Hbvaxpro

Hbvaxpro is a hepatitis B recombinant vaccine whose active ingredients are aluminium adjuvant and hepatitis B surface antigen (HBsAg) produced in Saccharomyces cerevisiae cells. It is supplied as an injectable preparation intended for intramuscular or subcutaneous use. The product is marketed in the European Union and is classified as a prescription vaccine; specific strength and dosage form are not currently disclosed in the source data.

Hbvaxpro is indicated for the prevention of hepatitis B virus infection in individuals who have not been previously immunized.

- Primary immunization series for infants, children, and adults. - Booster dose for persons previously vaccinated whose anti‑HBs levels have declined. - Use in high‑risk groups such as healthcare workers, dialysis patients, and individuals with chronic liver disease. - Administration before potential exposure to hepatitis B, including travel to endemic regions. - Inclusion in combination vaccination schedules when hepatitis B protection is required alongside other pediatric vaccines. - Vaccination of pregnant women at risk of hepatitis B exposure, following local clinical guidelines.

The safety profile of Hbvaxpro reflects that of other recombinant hepatitis B vaccines; most adverse events are mild, self‑limiting, and resolve without medical intervention.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Fatigue or mild headache. - Nausea or mild gastrointestinal discomfort. - Mild muscle aches or arthralgia. - Transient dizziness.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Neurological events including Guillain‑Barré syndrome (rare). - Severe local reaction with extensive necrosis (very rare). - Autoimmune phenomena such as systemic lupus erythematosus flare (extremely rare). - Severe hypotension or shock unrelated to anaphylaxis (extremely rare).

Before administering Hbvaxpro, healthcare providers should assess individual risk factors and follow standard vaccination precautions.

- Do not vaccinate individuals with a known severe allergy to any component, including aluminium salts. - Postpone vaccination in persons experiencing moderate or severe acute illness. - Observe the patient for at least 15 minutes after injection to detect immediate hypersensitivity. - Use caution in pregnant or lactating women; weigh potential benefits against unknown risks. - Evaluate immune status; immunocompromised patients may have a reduced antibody response. - Ensure proper storage and handling according to the manufacturer’s temperature requirements. - Record any previous hepatitis B vaccination history to determine need for booster dosing.

Hbvaxpro does not have extensive documented drug‑drug interactions, but certain concomitant therapies may influence vaccine response or safety.

Avoid: - Concurrent administration of other injectable vaccines at the same anatomical site. - Use of systemic corticosteroids or immunosuppressants at high doses that could blunt antibody formation.

Use with caution: - Antipyretics (e.g., acetaminophen, ibuprofen) taken prophylactically may reduce immunogenicity; use only if needed for symptom relief. - Live attenuated vaccines given within four weeks before or after Hbvaxpro, to avoid interference with immune response. - Blood products or immunoglobulins administered within 3 months, which may affect seroconversion rates.